Eli Lilly Export S.A. Puerto Rico Branch
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$61.0M
Doctors Paid
1,294
Transactions
10,868
2024 Total
$9.2M
Payment Breakdown by Category
Research$60.2M (98.8%)
Food & Beverage$215,942 (0.4%)
Consulting$107,349 (0.2%)
Travel$17,727 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $60.2M | 1,194 | 98.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $291,100 | 216 | 0.5% |
| Food and Beverage | $215,942 | 9,216 | 0.4% |
| Consulting Fee | $107,349 | 39 | 0.2% |
| Grant | $93,750 | 2 | 0.2% |
| Travel and Lodging | $17,727 | 68 | 0.0% |
| Education | $11,257 | 133 | 0.0% |
Payments by Type
Research
$60.2M
1,194 transactions
General
$737,125
9,674 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | $3.6M | 4 | 22 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | $2.4M | 4 | 28 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | $1.8M | 4 | 27 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | $1.7M | 2 | 11 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | $1.7M | 3 | 17 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | $1.6M | 6 | 22 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | $1.5M | 2 | 6 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | $1.4M | 5 | 24 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | $1.3M | 1 | 9 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | $1.3M | 6 | 25 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | $1.2M | 6 | 24 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | $1.1M | 0 | 6 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | $1.0M | 0 | 8 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | $1.0M | 1 | 9 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | $1.0M | 0 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | $917,236 | 4 | 17 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | $905,380 | 3 | 7 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY OF LY3471851 (NKTR 358) IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | $889,350 | 1 | 12 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | $857,290 | 2 | 9 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | $815,782 | 0 | 6 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | $759,841 | 1 | 5 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO AND ONCE-WEEKLY DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | $720,860 | 0 | 5 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | $713,486 | 1 | 3 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | $709,311 | 4 | 18 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | $693,087 | 2 | 7 |
| A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | $682,924 | 0 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | $674,235 | 4 | 18 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | $666,008 | 4 | 14 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | $650,274 | 0 | 4 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | $623,062 | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Alma Cruz Santana, Md, MD | Dermatology | Carolina, PR | $2.0M | $0 |
| Dr. Martha Gomez, Md, MD | Endocrinology, Diabetes & Metabolism | San Juan, PR | $1.3M | $0 |
| Amarilis Perez | Rheumatology | Caguas, PR | $600,710 | $0 |
| Dr. Altagracia Alcantara Gonzalez, M.d, M.D | Internal Medicine | Bayamon, PR | $579,690 | $0 |
| Dr. Luis Rivera, M.d, M.D | Specialist | San Juan, PR | $504,267 | $0 |
| Paola Mansilla-Letelier, M.d, M.D | Endocrinology, Diabetes & Metabolism | Guaynabo, PR | $486,694 | $0 |
| Dr. Juan Otero, M.d, M.D | Endocrinology, Diabetes & Metabolism | Caguas, PR | $300,861 | $0 |
| Jose Gonzalez Chavez, M.d, M.D | Dermatology | Santurce, PR | $142,902 | $0 |
| Dr. Ivonne De L Fraga Berrios, Md, MD | Neurology | San Juan, PR | $142,300 | $0 |
| Dr. Elba Perez, M.d, M.D | General Practice | Trujillo Alto, PR | $132,148 | $0 |
| Dr. Elizabeth Barranco, Md, MD | Internal Medicine | Ponce, PR | $127,938 | $0 |
| Mr. Gregorio Cortes-Maisonet, Md, MD | General Practice | San Juan, PR | $125,997 | $0 |
| Jose Santiago, Md, MD | Pediatric Gastroenterology | Ponce, PR | $122,977 | $0 |
| Dr. Kristina Utzschneider, Md, MD | Endocrinology, Diabetes & Metabolism | Seattle, WA | $110,125 | $0 |
| Dr. Ramon Ortiz Carrasquillo, M.d, M.D | Specialist | Manati, PR | $108,851 | $0 |
| Dr. Luis Pagan, Md, MD | General Practice | Dorado, PR | $107,675 | $0 |
| Monica Ortiz-Rivera, Md, MD | Internal Medicine | San Juan, PR | $94,011 | $0 |
| Angel Comulada | Endocrinology, Diabetes & Metabolism | Bayamon, PR | $87,789 | $0 |
| Odette Olivieri, Md, MD | Pediatrics | Ponce, PR | $82,101 | $0 |
| Dr. William Julio De Jesus, Md, MD | Psychiatry | Bayamon, PR | $78,139 | $0 |
| Dr. Carlos Pantojas, M.d, M.D | Rheumatology | San Juan, PR | $69,700 | $0 |
| Mirelis Acosta, M.d, M.D | Internal Medicine | San Juan, PR | $52,734 | $0 |
| Dr. Oscar Soto Raices, Md, MD | Rheumatology | San Juan, PR | $52,714 | $0 |
| Dr. Carmen Serrano, M.d, M.D | Neurology | San Juan, PR | $51,352 | $0 |
| Alex Gonzalez Bossolo, M.d, M.D | Student in an Organized Health Care Education/Training Program | San Juan, PR | $44,171 | $0 |
Ad
Top Products
- TALTZ $2.8M
- TRULICITY $1.1M
Payment Categories
- Food & Beverage $215,942
- Consulting $107,349
- Travel & Lodging $17,727
- Research $60.2M
About Eli Lilly Export S.A. Puerto Rico Branch
Eli Lilly Export S.A. Puerto Rico Branch has made $61.0M in payments to 1,294 healthcare providers, recorded across 10,868 transactions in the CMS Open Payments database. In 2024, the company paid $9.2M. The top product by payment volume is TALTZ ($2.8M).
Payments were distributed across 81 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($2.4M to 70 doctors).
Payment categories include: Food & Beverage ($215,942), Consulting ($107,349), Research ($60.2M), Travel & Lodging ($17,727).